Publications

Found 255 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
2024
Cerchietti L.  2024.  Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma.. Blood. 143(12):1101-1111.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al..  2024.  Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.
Maity D, Sivakumar N, Kamat P, Zamponi N, Min C, Du W, Jayatilaka H, Johnston A, Starich B, Agrawal A et al..  2024.  Profiling Dynamic Patterns of Single-Cell Motility.. Adv Sci (Weinh). :e2400918.
Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al..  2024.  XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.
Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al..  2024.  XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.
Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al..  2024.  XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.
2023
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.  2023.  The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.  2023.  The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.
Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.
Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.